Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krystal BiotechFRA:4KB -1.96%59 Debt-to-Equity is 0.01 as of Mar. 2026, which is at its 10-year median of 0.01. GuruFocus rates FRA:4KB with a GF Score™ of 59/100 and a GF Value™ of €268.15 (Fairly Valued). The stock has 2 warning signs investors should review. Among 965 Biotechnology companies, Krystal Biotech ranks better than 99.9% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Krystal Biotech's Debt-to-Equity or its related term are showing as below:
FRA:4KB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 6.38
Current: 0.01
During the past 10 years, the highest Debt-to-Equity Ratio of Krystal Biotech was 6.38. The lowest was 0.01. And the median was 0.01.
FRA:4KB's Debt-to-Equity is ranked better than 99.9% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs FRA:4KB: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Krystal Biotech Debt-to-Equity Related Terms
Krystal Biotech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs NUVL, HALO, APGE: Debt-to-Equity Comparison
For the Biotechnology subindustry, Krystal Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a Debt-to-Equity of 0.01 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Krystal Biotech and its competitors. This is near median its historical median of 0.01. Over the past decade, Krystal Biotech's Debt-to-Equity has ranged from 0.01 to 6.38. According to the industry distribution chart, Krystal Biotech ranks #1 out of 965 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is Krystal Biotech's Debt-to-Equity too high?
Krystal Biotech's current Debt-to-Equity of 0.01 is near median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 6.38. The Biotechnology industry median Debt-to-Equity is 0.16. Krystal Biotech's value of 0.01 is 93.8% below this industry median. Based on the distribution chart, Krystal Biotech ranks #1 out of 965 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Krystal Biotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Debt-to-Equity compare to NUVL and HALO?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #1 out of 965 companies for Debt-to-Equity. This places Krystal Biotech in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.16. Krystal Biotech's value of 0.01 is 93.8% below this benchmark. Historically, Krystal Biotech's own Debt-to-Equity has ranged from 0.01 to 6.38 over the past decade. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Krystal Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Debt-to-Equity of 0.01 is 93.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Debt-to-Equity is 0.01, which is near median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €268.15, compared to a current price of €284.40 — trading 6.1% above its estimated fair value. The current Debt-to-Equity is 0.01, which is near median its 10-year median of 0.01 and 93.8% below the Biotechnology industry median of 0.16. Krystal Biotech's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Debt-to-Equity is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €284.40 is trading 6.1% above its estimated GF Value™ of €268.15.
GuruFocus considers Krystal Biotech to be Fairly Valued.
Key valuation signals for FRA:4KB:
Debt-to-Equity: 0.01 (near median its 10-year median of 0.01)
GF Value™: €268.15 vs. price of €284.40 (6.1% above fair value)
Industry Position: 93.8% below the Biotechnology median (#1 of 965)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
59GF Score
Get the complete analysis for FRA:4KB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
